Electrolyte Inertia In Chronic Kidney Disease

Sourabh Sharma[1], Sanjay Kalra[2]

Abstract

Electrolyte imbalances are a common and challenging aspect of managing chronic kidney disease (CKD). Despite advances in treatment, a phenomenon known as "electrolyte inertia"- the inertness to correcting abnormal electrolyte levels- may persist in CKD patients. This inertia can result from various factors which include delayed therapeutic intervention, the complexity of multiple co-existing comorbidities, and the judicious balanced therapeutic approach necessitated by the multi-dyselectrolytaemia in CKD management. Through the concept of "electrolyte inertia," we explore the underlying causes for this phenomenon, its clinical implications, and strategies to overcome it, to achieve better patient care in CKD.

Keywords: Chronic kidney disease, electrolytes, hyperkalaemia, hyperphosphataemia, hypocalcaemia, hyponatraemia

DOI: https://doi.org/10.47391/JPMA.25-30

Introduction

Chronic kidney disease (CKD) is defined as abnormalities of kidney structure or function, present for a minimum of three months, with implications for health.[1] CKD is a progressive condition characterized by the gradual loss of kidney function, often leading to disturbances in electrolyte balance.[2-4] Electrolytes such as potassium, sodium, calcium, magnesium, and phosphate are tightly regulated by the kidneys, and their dysregulation can have significant clinical consequences (Table 1). We propose the term "electrolyte inertia" referring to the observed delay or inertness in correcting these electrolyte imbalances, even when they are identified in clinical settings. This phenomenon is particularly concerning in CKD patients, where the consequences of untreated or poorly managed multi-dyselectrolytaemia can exacerbate disease progression and increase the risk of complications. Understanding the underlying causes of electrolyte inertia and addressing it effectively is crucial for improving patient outcomes in CKD.

[1]Department of Nephrology, VMMC & Safdarjung Hospital, New Delhi, India
[2]Department of Endocrinology, Bharti Hospital, Karnal, India; University Center for Research & Development, Chandigarh University, Mohali, India
Correspondence: Dr Sanjay Kalra, **Email:** brideknl@gmail.com
ORCID ID: https://orcid.org/0000-0003-1308-121X?lang=en

Causes of Electrolyte Inertia in CKD

Electrolyte inertia is a multifaceted issue with various causes, including medical, systemic, and patient-related factors. One primary cause is the complexity of managing multi-dyselectrolytaemia simultaneously, which often requires a judicious balanced approach to avoid exacerbating one imbalance while correcting another. For example, aggressive overzealous management of hyperkalaemia might lead to hypokalaemia, which can have equally serious consequences[5]. Another contributing factor is the cautious approach often adopted in CKD management due to the narrow therapeutic window for many interventions. Clinicians may hesitate to initiate or escalate treatment due to concerns about adverse effects, particularly in patients with advanced CKD or multiple comorbidities. Additionally, delays in therapeutic intervention, whether due to logistical challenges, patient non-adherence, or clinical inertia, can perpetuate electrolyte imbalances, leading to a cycle of persistent dysregulation. Various causes for electrolyte inertia have been outlined hereby:

A. Intrinsic causes-

1. Complex Pathophysiology of CKD

Altered renal excretion and hormonal dysregulation can lead to unpredictable electrolyte imbalances (e.g., hyperkalaemia, hyperphosphataemia).[2,3]

2. Psychological and Behavioural Causes

Inertia from Fear of Adverse Effects: Hesitation to modify RAAS inhibitors due to fear of worsening kidney function.[12]

Acceptance of Suboptimal Status Quo: Perception that mild-to-moderate disturbances are "normal" in CKD and do not require aggressive intervention.

3. Patient-Related Causes

Poor Adherence to Treatment: Noncompliance with dietary restrictions (e.g., low potassium, low phosphorus diets); and irregular intake of prescribed medications due to forgetfulness or financial constraints.[9]

Lack of Awareness: Limited understanding of the implications of electrolyte imbalances.[10]

Socioeconomic Factors: Financial challenges impacting

access to healthcare and medications.[11]

B. Extrinsic causes-

1. Iatrogenic causes (Physician related)

Polypharmacy: Use of multiple drugs (e.g., RAAS inhibitors, diuretics) complicates electrolyte management.[2-4]

Focus on Comorbidities: Priority given to comorbidities like diabetes, hypertension, and cardiovascular disease over electrolyte disturbances.

Healthcare Provider Barriers: Overestimation of tolerance to chronic disturbances; and reluctance to aggressively treat due to potential side effects (e.g., hyperkalaemia from RAAS inhibitors).

2. Clinical and Systemic Causes

Diagnostic Gaps: Delays in identifying electrolyte abnormalities due to infrequent or inconsistent laboratory monitoring.

Variability in Treatment Guidelines: Lack of uniform consensus on management thresholds for certain electrolytes (e.g., potassium).[6]

Cost of Treatment: High cost or in certain countries, non-availability of newer therapeutic options like potassium binders or phosphate binders can delay or limit usage.[7,8]

3. Healthcare System-Related Causes

Infrequent Monitoring: Limited availability of routine laboratory tests in under-resourced settings.[10,11]

Time Constraints: Short clinic visits leading to inadequate time to address electrolyte disturbances comprehensively.

Clinical Implications of Electrolyte Inertia

The persistence of electrolyte imbalances in CKD patients due to inertia can have several detrimental effects. Uncorrected hyperkalaemia, for example, increases the risk of life-threatening cardiac arrhythmias, while persistent hyperphosphataemia can contribute to vascular calcification and progression of CKD2,.[3,5] Similarly, imbalances in sodium and calcium levels can lead to fluid overload, hypertension, bone disorders, and increased mortality.[13,14]

Electrolyte inertia also complicates the management of CKD by contributing to a chronic state of instability, where the patient remains at risk for acute exacerbations. This instability can result in more frequent hospitalizations, a higher burden of disease, and a reduced quality of life for patients. Various clinical implications have been outlined here[2-5,13-16](Figure 1):

1. Cardiovascular Risk: Untreated electrolyte disturbances (e.g., hyperkalaemia, hypokalaemia, hyperphosphataemia) can lead to arrhythmias, vascular calcification, and heart failure.

2. CKD Progression: Inadequate management can worsen kidney damage by perpetuating metabolic imbalances, acid-base disturbances, and nephrotoxic effects.

3. Skeletal Complications: Persistent hyperphosphataemia and hypocalcaemia contribute to secondary hyperparathyroidism, renal osteodystrophy, fractures, and poor bone mineral density.

4. Neuromuscular Dysfunction: Chronic hyperkalaemia or hypokalaemia can cause muscle weakness, cramps, paralysis, or tetany, affecting quality of life.

5. Increased Hospitalisations: Acute exacerbations, such as severe hyperkalaemia or acidosis, can necessitate emergency care or dialysis initiation.

6. Medication Challenges: Unaddressed electrolyte imbalances may force discontinuation of RAAS inhibitors or other essential drugs, worsening CKD outcomes.

7. Metabolic Complications: Long-standing imbalances, like metabolic acidosis or hyperkalaemia, exacerbate protein catabolism, inflammation, and oxidative stress.

8. Worsening Mortality: Persistent electrolyte abnormalities are associated with higher risks of cardiovascular and all-cause mortality in CKD patients.

9. Quality of Life Decline: Chronic symptoms such as fatigue, bone pain, or muscle dysfunction impair daily activities and overall well-being.

10. Economic Burden: Increased healthcare utilization and costs due to preventable complications of electrolyte disturbances.

Strategies for Overcoming Electrolyte Inertia

To address electrolyte inertia in CKD, a multifaceted approach is required (Table 1). First, early identification and proactive management of electrolyte disturbances are essential.[2-4] This can be achieved through regular monitoring of electrolyte levels and the use of predictive tools to anticipate imbalances before they become clinically significant.

Second, a more aggressive yet carefully balanced approach to treatment may be necessary. This includes the judicious use of medications such as potassium



Figure-1: Clinical implications of electrolyte inertia in CKD.

binders, phosphate binders, and diuretics, with close monitoring to avoid overcorrection and subsequent adverse effects. Personalized treatment plans that consider the individual patient's overall health, stage of CKD, and comorbidities can help mitigate the risks associated with aggressive management.

Third, enhancing patient education and engagement is crucial. Educating patients about the importance of dietary restrictions, medication adherence, and regular follow-up can improve their involvement in managing their condition and reduce the likelihood of inertia due to non-adherence.[17,18]

Finally, healthcare systems need to address logistical barriers to timely treatment, such as ensuring prompt

Table-1: Strategies for overcoming electrolyte inertia

Strategies for overcoming electrolyte inertia	
Enhanced Monitoring	**Regular Lab Testing:** Frequent monitoring of serum electrolytes based on CKD stage
	Point-of-Care Testing: Utilize rapid diagnostics to detect acute abnormalities
	Electronic Alerts: Implement electronic health record (EHR) systems with alerts for abnormal levels
Optimized Medical Management	**Individualization:** Consider CKD stage, comorbidities, and patient-specific needs
	Medication Adjustments: Use new therapies to mitigate risks
	Aggressive Treatment: Do not delay initiation of interventions
Patient Education	**Dietary Counseling:** Educate patients on low-potassium, low-phosphate, and balanced sodium diets
	Self-Monitoring Tools: Introduce home monitoring devices for blood pressure, glucose, or body weight
	Awareness Campaigns: Use educational materials to improve understanding of symptoms and risks
Healthcare Delivery	**Multidisciplinary Teams:** Collaborate with nephrologists, dietitians, pharmacists, and primary care providers for holistic management
	Timely Referrals: Facilitate timely access to nephrology care
	Accessible Medications: Advocacy for cost-effectiveness and insurance coverage
Guideline Adherence	**Evidence-Based Protocols:** Develop standardized protocols based on KDIGO and other guidelines
	Provider Education: Conduct workshops and webinars to update clinicians on best practices
	Clinical Decision Tools: Use tools that provide dose adjustment recommendations
Systemic Challenges	**Healthcare Access:** Expand access to diagnostic facilities and essential medications
	Telemedicine: To monitor and manage patients remotely
	Policy Advocacy: Integrate electrolyte management into national CKD care programmes
Prevention	**Risk Stratification:** Identify high-risk patients for close monitoring
	Dietary Interventions: Introduce population-level dietary programmes
	Public Awareness: Increase public knowledge about the risks of CKD-related electrolyte disturbances.

access to necessary medications and reducing delays in care transitions.[19,20] Implementing protocols for rapid intervention when electrolyte imbalances are detected can also help overcome inertia.

Conclusion

Electrolyte inertia is a significant challenge in the management of chronic kidney disease, with serious implications for patient outcomes. By understanding the causes of inertia and implementing strategies to address it, clinicians can improve the management of electrolyte imbalances and enhance the overall care of CKD patients. Proactive, personalized, and coordinated care is essential in overcoming electrolyte inertia and reducing its impact on the progression of CKD and patient quality of life.

Disclaimer: None.

Conflict of Interest: None.

Source of Funding: None.

References

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105:S117-S314.
2. Dhondup T, Qian Q. Electrolyte and Acid-Base Disorders in Chronic Kidney Disease and End-Stage Kidney Failure. Blood Purif. 2017;43:179-188.
3. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019;322:1294-1304.
4. Elendu C, Elendu RC, Enyong JM, Ibhiedu JO, Ishola IV, et al. Comprehensive review of current management guidelines of chronic kidney disease. Medicine (Baltimore). 2023;102:e33984.
5. Lehnhardt A, Kemper MJ. Pathogenesis, diagnosis and management of hyperkalemia. Pediatr Nephrol. 2011;26:377-84.
6. Bosch NA, Vail EA, Law AC, Homer-Bouthiette C, Walkey AJ, Moitra VK. Practice Patterns and Outcomes of Potassium Repletion Thresholds during Critical Illness. Ann Am Thorac Soc. 2024;21:456-463.
7. Rizk, R. Cost-effectiveness of phosphate binders among patients with chronic kidney disease not yet on dialysis: a long way to go. BMC Nephrol. 2016;17:75.
8. Zannad F, Ferreira JP, Pitt B. Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments. Eur Heart J Suppl. 2019;21(Suppl A):A55-A60.
9. Kaesler N, Baid-Agrawal S, Grams S, Nadal J, Schmid M, Schneider MP, et al. Low adherence to CKD-specific dietary recommendations associates with impaired kidney function, dyslipidemia, and inflammation. Eur J Clin Nutr. 2021 ;75:1389-97.
10. Ahmed J, Azhar S, Ul Haq N, Hussain S, Stájer A, Urbán E, et al. Awareness of Chronic Kidney Disease, Medication, and Laboratory Investigation among Nephrology and Urology Patients of Quetta, Pakistan. Int J Environ Res Public Health. 2022;19:5015.
11. Ng MSN, Chan DNS, So WKW. Health inequity associated with financial hardship among patients with kidney failure. PLoS One. 2023;18:e0287510.
12. Humphrey TJL, James G, Wittbrodt ET, Zarzuela D, Hiemstra TF. Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD). Clin Kidney J. 2021 ;14:2203-2212.
13. Shin J, Lee CH. The roles of sodium and volume overload on hypertension in chronic kidney disease. Kidney Res Clin Pract. 2021;40:542-554.
14. Moe SM. Calcium as a cardiovascular toxin in CKD-MBD. Bone.

2017;100:94-99.
15. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021;143:1157-1172.
16. Gregg LP, Bossola M, Ostrosky-Frid M, Hedayati SS. Fatigue in CKD: Epidemiology, Pathophysiology, and Treatment. Clin J Am Soc Nephrol. 2021;16:1445-1455.
17. Beto JA, Schury KA, Bansal VK. Strategies to promote adherence to nutritional advice in patients with chronic kidney disease: a narrative review and commentary. Int J Nephrol Renovasc Dis. 2016 2;9:21-33.
18. Jimmy B, Jose J. Patient medication adherence: measures in daily practice. Oman Med J. 2011;26:155-9.
19. Clarke JL, Bourn S, Skoufalos A, Beck EH, Castillo DJ. An Innovative Approach to Health Care Delivery for Patients with Chronic Conditions. Popul Health Manag. 2017 ;20:23-30.
20. Rosen MA, DiazGranados D, Dietz AS, Benishek LE, Thompson D, Pronovost PJ, Weaver SJ. Teamwork in healthcare: Key discoveries enabling safer, high-quality care. Am Psychol. 2018;73:433-450.